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Active neuropeptide Y receptors were solubilized 
from rabbit kidney membranes using the zwitterionic 
detergent 3-[ (3-cholamidopropy l)dimethylammonio ]-
1-propanesulfonic acid (CHAPS). In membrane frag-
mentsandsoluble extracts neuropeptide Y bindingwas 
time dependent, saturable, reversible, and of high af-
finity. Scatchard analysis of equilibrium binding data 
indicated a single class of binding sites with respective 
Kn and Bmax values of 0.09 nM and 530 fmol/mg of 
protein for the membrane-bound receptors and 0.10 
nM and 1585 fmol/mg of protein for the soluble recep-
tors. Neuropeptide Y bindingwas specifically inhibited 
by the nonhydrolyzable GTP analog guanosine 5' -0-
(3-thiotripbosphate) in a concentration-dependent 
manner, with IC5o values of 28 and 0.14 ~o~oM for mem-
brane-bound and soluble receptors, respectively, sug-
gesting that neuropeptide Y receptors are functionally 
coupled to GTP-binding regulatory proteins. Cross-
Hoking studies were performed with the heterobi-
functional N-hydroxysuccinimidyl-4-azidobenzoate 
and the monofunctional neuropeptide Y derivative, 
azidobenzoyl and led to the identification of a 100 kDa 
peptide that should represent the covalently labeled 
neuropeptide Y receptor. 
Neuropeptide Y (NPY) 1 is a 36-amino acid peptide struc-
turally related to a group of brain-gut peptides, the so-called 
pancreatic polypeptide family. Although the other members 
of this family, pancreatic polypeptide and peptide YY, occur 
mainly in endocrine cells in the intestinal tract, neuropeptide 
Y is predominantly found in brain and the peripheral nervous 
systern (1, 2). In sympathetic nerves it is co-localized and 
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released together with norepinephrine, with which it interacts 
both on a presynaptic and postsynaptic Ievel (3-5). Physio-
logical effects of neuropeptide Y resemble those elicited by 
noradrenergic stimulation. The peptide is an extremely potent 
constrictor of small blood vessels in rnany vascular beds and 
increases blood pressureinan adrenoreceptor-resistant man-
ner when adrninistered systematically (6). Injection into the 
brain stirnulates food intake, decreases blood pressure, and 
causes neuroendocrine alterations. Peptide YY exerts quite 
similar effects, suggesting that both peptides can activate the 
same receptors (7). · 
Binding sites for neuropeptide Y have been described in 
numerous tissues including brain (8), spieen (9), aorta (10), 
and dorsal root ganglia (11). Although there is some indirect 
evidence that at least one type of neuropeptide Y receptor 
belongs to the class of G-protein coupled receptors (9, 12, 13), 
little is known about the structure and rnolecular properties 
of neuropeptide Y receptors. 
W e report here on some experirnents aimed at character-
izing neuropeptide Y binding sites on rabbit kidney mem-
branes and present a protocol that allows solubilization of 
neuropeptide Y receptors in an active form. The rabbit kidney 
was chosen because this organ was recently reported to pos-
sess a particularly high density of high affinity binding sites 
for neuropeptide (Y) (14). 
EXPERIMENTAL PROCEDURES 
Materials-Neuropeptide Y was purchased from Bachern (Heidel-
berg, Federal Republic of Germany). Monoiodo 1251-labeled Lys4 
neuropeptide Y and Na1251, carrier-free, were purchased from Amer-
sham Corp. The other chemieals were obtained from the following 
sources. N-Hydroxysuccinimidyl 4-azidobenzoate (NHSAB), 
CHAPS, phenylmethylsulfonyl fluoride, leupeptin, bacitracin, and 
the molecular weight markers for sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) were from Sigma; N,N'-
dimethylformamide was from Merck; and chloramine T, bovine serum 
albumin, and all other chemicals, except stated otherwise, were pur-
chased from Serva (Heidelberg, F. R. G. ). 
Preparation of Rabbit Kidney Membranes-Decapsulated rabbit 
kidneys (about 5 g each) were placed in 20 ml of homogenization 
buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM 
EGTA, 1 mM phenylmethylsulfonyl fluoride, and 0.5% bacitracin. 
The tissue was finely minced with a polytron (setting 10) and homog-
enized with six strokes of a Teflon pestle in a tight fitting glass vessel. 
This homogenate was centrifuged for 10 min at 800 x g, the pellet 
discarded, and the supernatant centrifuged at 50,000 X g for 30 min 
in a Sorvall SS-34 rotor. The upper creamy layer of this pellet was 
gently removed, suspended in 20 ml of homogenization buffer, and 
recentrifuged at 50,000 X g for 30 min. The whole pellet was washed 
three times with homogenization buffer. The finalmembranepellet 
was resuspended at a protein concentration of approximately 10 mg/ 
ml homogenization buffer and shortly minced with a Polytron (setting 
5). The designated membrane fragments were frozen in aliquots and 
stored at -20 oc. 
Receptor Solubilization-The membrane fragm.ents were thawed 
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and diluted in EGTA-free homogenization buffer containing various 
arnounts of CHAPS in order to deterrnine the optimal conditions for 
solubilization. After rnixing gently for various tirnes at 4 ·c, the 
extract was ultracentrifuged at 150,000 x g for 1 h in a Heckman type 
Tl-45 rotor. The supernatant was pressed through a 0.22-#Lm filter 
(Schleicher & Schüll) and is designated solubilized fraction. 
Receptor Binding Studies with Membrane-bound and CHAPS-
solubilized Receptors-All binding experirnents were carried out at 0 
or 25 ·c in a total volume of 400 J.tl/tube for both the membrane 
fragments and the solubilized fraction. 
The binding assay buffer contained 50 mM Tris-HCl, pH 7.4, 5 rnM 
MgCh, 0.1% bovine serum albumin, 0.1% bacitracin, 0.1 mg/ml 
aprotinin, 0.1 mg/rnl soybean trypsin inhibitor, and 10 J.tg/mlleupep-
tin. The solubilized fraction was adjusted to a final concentration of 
3 rnM CHAPS. The Iigand binding to the mernbranes was terminated 
by rapid filtration through GF /C filters (Whatman) and three washes 
with 3 ml each of ice-cold buffer containing 50 mM Tris-HCl, pH 7.4, 
and 5 mM MgCb. The filters were dried, and the radioactivity was 
counted in a -y-spectrometer (multicrystal counter, Berthold, LB 
2105). The binding of the solubilized fraction was stopped by the 
addition of 400 J.tl of an ice-cold dextran-coated charcoal suspension 
containing 3% Norit A (Serva) and 0.4% dextran in 50 rnM Tris-HCI, 
pH 7.4, containing 5 rnM MgCl~. After 3 min on ice the tubes were 
centrifuged at 14,000 X g for 2 min, thus separating bound and free 
neuropeptide Y. The supernatants were decanted and measured for 
radioactivity in the spectrorneter. 
Nonspecific bindingwas deterrnined by incubation in the presence 
of excess unlabeled neuropeptide Y (0.5 J.tM). 
Saturation Experiments-Membrane fraction proteins and solubi-
lized extracts were incubated for 60 rnin at 25 ·c with increasing 
concentrations of a mixture of 12~1-neuropeptide Y and unlabeled 
neuropeptide Y (final concentration, 10-2500 pM). The binding pa-
rameters of the saturation curves were estimated using the nonlinear 
least squares curve-fitting program SCTFIT (15). 
Kinetic Experiments-Membrane and solubilized fractions were 
incubated with 125!-neuropeptide Y (0.4 nM). Association data were 
obtained by deterrnining the specific binding at different tirnes. At 
equilibriurn of the reaction, dissociation was started by the addition 
of excess unlabeled neuropeptide Y ( 1 J.tM), and the time course of 
the specific binding was measured. 
Preparation of Photolabile 1251 -Azidobenzoate Neuropeptide Y-The 
azidobenzoate derivative of neuropeptide Y was prepared by the 
following procedure. All steps with the photolabile reagent were 
handled in the dark. 
Thirty J.tg of neuropeptide Y (7 nmol) in 30 #Ll of water was added 
to 30 J.tl of 50 mM HEPES, pH 8.0. To initiate the reaction, 7 nmol 
of NHSAB dissolved in 5 "'1 of dimethylformamide was added to the 
reaction mixture and incubated overnight at 4 oc. The reaction was 
quenched by the addition of 3 #Ll of 1 M Tris-HCl, pH 7.4, for 2 hat 
room ternperature. The reaction products were separated in a re-
versed-phase HPLC system (Spectra Physics, Darrnstadt) consisting 
of a 3.9 x 30-cm Delta Pak C-4 column (15-"'rn particles, 300 A pore 
size, Millipore, Waters Chrornatography Div., Eschborn, F. R. G.} as 
described (16). The column was equilibrated in 20% acetonitrile in 
0.65% trifluoroacetic acid, and the elution was performed with an 
acetonitrile gradient of 20-40% over 50 rnin at a flow rate of 2 ml/ 
min. The chromatography was followed by automatic recording of 
the absorbance at 220 nrn. One-minute fractions were collected. The 
elution profile (Fig. 1) shows (without the injection peak) three rnajor 
peak fractions that were lyophilized and analyzed for their ability to 
inhibit 12"1-neuropeptide Y binding to rabbit kidney membranes. 
Although the first peak represents unaltered neuropeptide Y, as could 
be dernonstrated by equivalent retention tirnes of neuropeptide Y in 
control HPLC runs under the sarne elution conditions, the two other 
peptides could be identified as neuropeptide Y derivatives in receptor 
binding studies. The neuropeptide Y rnolecule possesses two readily 
accessible arnino groups for covalent attachment of the aminoactive 
ester group of NHSAB, Lys4 and the N-terrninal Tyr1• In accordance 
with this the two rnain reaction products should correspond to mono-
and diazidobenzoyl derivatives of neuropeptide Y. The designated 
azidobenzoyl neuropeptide Y (AB-NPY) (see Fig. 1, fraction nurober 
34) was iodinated by the chloramine-T procedure and was confirrned 
to be an azidobenzoyl derivative by its ability to photolabet rabbit 
kidney rnembranes. 
For preparation of 12€>1-azidobenzoyl neuropeptide Y, 5 J,tg of azi-
dohenzovl neurooeotide Y in a volume of 20 ul of 0.25 M NaP, buffer 
metabisulfite (1 mg/ml). Free iodine was removed by chromatography 
on a C1R Sep-Pak cartridge. Elution was performed stepwise with 10-
100% methanol in 0.1% trifluoroacetic acid. The iodinated azido-
benzoyl neuropeptide Y eluted at 80% methanol. 
Af{inity Labeling of Neuropeptide Y Binding Sites-Membrane 
fractions (100 IJg/ml) were incubated with 100 pM 1251-neuropeptide 
Y (2,000 Ci/mmol) in rnembrane binding assay buffer for 4 h at 0 ·c. 
Membrane-bound labeled neuropeptide Y was separated by centrifu-
gation at 14,000 x g for 15 min at 4 ·c. The rnembranes were washed 
twice with ice-cold 50 mM HEPES, pH 7.4, containing 5 mM MgCl2 
and were finally resuspended in 300 J.tl of this buffer. The cross-
linking reagent NHSAB was added to the membrane fragments at a 
final concentration of 1 mM (50 'mM stock in dimethylformamide). 
After 5 rnin in darkness the samples with the photoreactive NHSAB 
were exposed to UV light (Mineralight TM-15) for 15 min at 0 ·c. 
The reaction was then quenched by the addition of 20 #Ll of 3 M Tris, 
pH 6.8, and the rnembranes were pelleted by centrifugation at 14,000 
x g for 10 rnin at 4 ·c. 
In studies with the photolabile neuropeptide Y derivative, the 
rnembranes were incubated with 0.4 nM 1251-azidobenzoyl neuropep-
tide Y in a total volume of 400 J.tl of rnembrane binding assay buffer 
for 4 hat 0 ·c in darkness. The membranes were centrifuged at 14,000 
x g for 15 min at 4 ·c and resuspended in 300 ~-Ll of 50 rnM HEPES, 
pH 7.4, containing 5 mM MgC12• Afterirradiation with UV light for 
15 rnin at 0 ·c the samples were handled further as described above. 
In competition experirnents, membranes were incubated with 1251-
neuropeptide Y and increasing concentrations of unlabeled neuropep-
tide Y (10-7 to 10-11 M). The pelleted membranes were analyzed by 
SDS-PAGE. 
SDS-PAGE and Autoradiography-The membrane pellets were 
solubilized in sample buffer containing 125 mM Tris-HCI, pH 6.8, 
bromphenol blue, 10% (v/v) glycerol, and 2% (w/v) SDS in the 
presence or absence of 100 mM dithiothreitol. The samples were 
boiled for 3 min, and SDS-PAGE was performed according to Laem-
mli (17) with a 3.75% stacking and a 10% polyacrylamide resolving 
gel. After visualizing the proteins with Coomassie Blue R-250, the 
gels were destained and dried. A utoradiography was performed for 2-
4 weeks at -70 ·c on Kodak X-Ornat AR filrns with Kodak X-Omatic 
regular intensifying screens. 
Protein Determination-Protein concentrations in the mernbrane 
and soluble fractions were determined according to a modified Lowry 
rnethod (18) using bovine serum albumin as a standard. 
RESULTS 
The Effect of Different CHAPS Concentrations on the Sol-
ubilization of Neuropeptide Y Binding Activity-Rabbit kid-
ney membranes were treated for different times at 0 oc with 
various concentrations of the zwitterionic detergent CHAPS 
in order to determine the optimal conditions for solubilization 
of active neuropeptide Y receptors. The highest amount of 
specific neuropeptide Y binding activity with about 40% of 
the membrane proteins being solubilized was measured in the 
concentration range between 6 and 9 mM CHAPS. Although 
the total neuropeptide Y binding remained quite unchanged 
at higher CHAPS concentrations up to 20 mM, the nonspecific 
binding increased continuously parallel with a rising amount 
of solubilized membrane proteins. Incubation times Ionger 
than 40 min did not yield more receptor activity; therefore, 
solubilization with 8 mM CHAPS for 40 min at 0 oc was 
selected for all subsequent studies. The 1251-neuropeptide Y 
binding activity present in both the membrane and solubilized 
fractions was stahle for at least 10 days at 4 oc. 
Equilibrium Binding of Neuropeptide Y to Membrane Prep-
arations and Soluble Extracts-Saturation experiments with 
neuropeptide Y were performed in membrane fragments and 
CHAPS-solubilized fractions in order to determine and com-
pare the binding parameters in both extracts (Fig. 2). In either 
case the specific binding of 1251-neuropeptide Y was saturable, 
and their analyses by a nonlinear curve-fitting program (15) 
indicate a single class of high affinity binding sites, as shown 
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FIG. 1. HPLC purification of AB-
NPY. Equimolar amounts of neuropep-
tide Y and NHSAB (7 nmol each) were 
aHowed to react at 4 ·c overnight in 
darkness (for details, see "Experimental 
Procedures"). The reaction mixturewas 
quenched in 60 mM Tris-HCI, pH 7.4, 
for 2 h at room temperature and was 
applied to a C-4 column equilibrated in 
20% acetonitrile in 0.065% trifluoroace-
tic acid. The elution was performed with 
an acetonitrile gradient of 20-40% 
( · · · ) over 50 min at a flow rate of 2 
ml/min. One-minute fractions were col-
lected, and the main peak fractions, de-
tected by their absorbance at 220 nm, 
were lyophilized and tested in the recep-
tor binding assay. Fraction 34, the des-
ignated AB-NPY, was iodinated by the 
chloramine-T procedure and further 
analyzed prior to its employment for 
photocross-linking. 
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respective Bmax and Kv values were 530 ± 70 fmol/mg of 
protein and 0.09 ± 0.02 nM for the membrane-bound recep-
tors, and 1585 ± 130 fmol/mg of protein and 0.10 ± 0.02 nM 
for the CHAPS-solubilized receptors. Although unaltered dis-
sociation values in both extracts demoostrate equal affinities 
of the receptors for neuropeptide Y, the higher number of 
binding sites (Bmax) for the soluble fraction suggests an about 
3-fold enrichment of neuropeptide Y receptors during the 
solubilization procedure. Nonspecific binding, expressed as 
per cent of totalligand bound at the Kv, decreased from about 
25% for the membrane preparations to about 10% for the 
soluble extract, which might also be due to the effective 
separation of free and bound radioligand by dextran-coated 
charcoal adsorption in the case of the CHAPS-solubilized 
1 
fraction. 
Kinetics of 1251-Neuropeptide Y Binding to Membranesand 
Soluble Fractions-Association and dissociation of neuropep-
tide Y binding to membranes and CHAPS-solubilized frac-
tions were carried out at 25 oc (Fig. 3) and 0 oc. For both 
fractions binding was rapid, with 80% of maximal binding 
occurring within 10 min, and it reached a steady state at 
about 40 min. Neuropeptide Y binding remained stable over 
a period of at least 4 h at this temperature. At 0 oc half-
maximal neuropeptide Y binding was obtained after about 40 
min, and steady state was reached after 230 min ( data not 
shown). After association to equilibrium, dissociation was 
initiated by the addition of 1 p.M unlabeled neuropeptide Y. 
As shown in Fig. 3, neuropeptide Y binding was reversible but 
with a slow dissociation rate for both the membranes and the 
solubilized preparation. In order to test the possible role of G 
proteins in this process, we investigated the effect of guanine 
nucleotides on the time course of dissociation. The addition 
of the nonhydrolyzable GTP'YS at a final concentration of 0.1 
mM caused a dramatic increase of the dissociation rate. 
Within 5 min of incubation the specific 125!-neuropeptide Y 
binding declined to about 30% for the membranes (Fig. 3A) 
and to less than 15% for the solubilized fraction (Fig. 3B). In 
control studies, ATP'YS administered at an equal concentra-
tion of 0.1 mM did not alter neuropeptide Y binding at all (for 
... ······· 
.. 
.. 
.. 
.. ·· 
.... 
tll 
AB-IPY-i 
IPY-
.. 
.. 
.. 
.. ·· .. 
.. 
.. 
.. 
I 
... 
311 
.. ········ 
.. 
.. 
.. 
... ····· 
.. 
40 ... 
fr•etl•• •••••• 
.. 
••• 40 
... ··· 
20 
110 
'i/1. 
• 
" •..
• :1 
... 
.. 
.. 
... 
-• 
membranes) or only to a very slight extent (for soluble frac-
tions). 
I nfluence of N ucleotides on Neuropeptide Y Binding-Since 
we could demoostrate G-protein interaction with neuropep-
tide Y receptors for membrane-embedded as weil as for 
CHAPS-solubilized binding sites in the previous dissociation 
study, we performed a dose-response relationship between 
neuropeptide Y binding and concentration of GTP and its 
stable analogs (lo-s to 10-3 M). As depicted in Fig. 4, neuro-
peptide Y binding decreased in the presence of GTP")'S in a 
concentration-dependent manner, with an ICso of about 28 
ß.LM GTP'YS for the membranes (Fig. 4A) and 0.14 ß.LM GTP'YS 
for the soluble fraction (Fig. 4B), respectively. Experiments 
with Gpp(NH)p provided similar results; however, GTP was 
about 5-10-fold less potent (not shown). The inhibitory influ-
ence on neuropeptide Y binding to both fractions was guanine 
nucleotide specific, since A TP and its analogs caused far less 
pronounced effects. 
Affinity Labeling of Neuropeptide Y Receptors-For further 
characterization of the neuropeptide Y receptors we per-
formed cross-linking sturlies to rabbit kidney membranes with 
the heterobifunctional photoreactive NHSAB and with AB-
NPY. 
The azidobenzoyl neuropeptide Y was prepared as described 
under "Experimental Procedures." In competition experi-
ments neuropeptide Y inhibited the binding of 1251-azidoben-
zoyl neuropeptide Y to rabbit kidney membranes with an ICso 
of 0.40 ± 0.08 nM (not shown). Nonspecific binding of this 
photolabile neuropeptide Y derivative was exceedingly high 
(about 70% of total Iigand bound), a fact that might account 
for the numerous covalently labeled polypeptides obtained by 
photocross-linking 125!-azidobenzoyl neuropeptide Y to rabbit 
kidney membranes (see Fig. 5A). However, when excess un-
labeled neuropeptide Y (0.1 p.M) was used for competition, 
one distinct band with a molecular mass of about 100 kDa 
was displaced (Fig. 5A, arrow). 
Experiments with the heterobifunctional photolabile 
NHSAB resulted in substantiallabeling of the 100-kDa com-
plex. The dried gels were subjected to prolonged autoradiog-
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FIG. 2. Saturation curves and Scatchard analyses of neu-
ropeptide Y binding to membrane preparations (panel A) and 
to CHAPS-solubilized fractions (panel B). Rahbit kidney mem-
branes (35 J.Lg/ml) and CHAPS-solubilized fractions (20 JLg/ml) were 
incubated with increasing concentrations of 1251-neuropeptide Y at 
25 oc for 60 min. The bound radioactivity was separated from the 
free Iigand by filtration for the membrane fragments and by dextran-
coated charcoal adsorption for the soluble extract (for details, see 
"Experimental Procedures"). Nonspecific binding (0--0) was de-
termined in the presence of0.5 JLM unlabeled neuropeptide Y. Specific 
binding (..___.)was estimated by subtracting nonspecific binding 
from total Iigand bound. The inset shows the appropriate Scatchard 
plots: B, specifically bound neuropeptide Y in fmol/mg of protein; F, 
free neuropeptide Y in nM. Each point is an average of a triplicate 
determination. The binding parameters were fit using a nonlinear 
curve-fitting program (15). 
raphy in order to expose nonspecific labeling. as illustrated in 
Fig. 5B. 
Competition sturlies were performed for both cross-linkers 
and commonly showed displacement of the specifically labeled 
100-kDa complex by unlabeled neuropeptide Y in the nano-
molar concentration range, as demonstrated in Fig. 5B. There 
were no changes in the labeling pattern regardless of whether 
the cross-linking reactions were analyzed under reducing (100 
mM dithiothreitol) or nonreducing conditions. 
DISCUSSION 
In the present study we demonstrate solubilization of neu-
ropeptide Y receptors from rabbit kidney membranes in an 
for the solubilization of numerous peptide receptors including 
those for angiotensin li (19), neurotensin (20), vasoactive 
intestinal peptide (21), and vasopressin (22). The soluble state 
of the receptors was confirmed by two experimental criteria. 
Neuropeptide Y binding activity passed through 0.22-J.tm fil-
ters and did not decrease following further ultracentrifugation 
at 150,000 x g for 60 min. The receptor characteristics re-
mained unaltered during the solubilization procedure as was 
shown by saturation studies. In addition, neuropeptide Y 
binding to both membranes and soluble extracts was time 
dependent, saturable, and reversible. Although association of 
neuropeptide Y to its binding sites was quite rapid, dissocia-
tion occurred in a surprisingly slow fashion. However, the 
addition of GTP or its analogs accelerated drastically the 
dissociation of receptor-bound neuropeptide Y. This suggests 
that guanine nucleotides may regulate the binding of this 
peptide by triggering conversion of high into low affinity 
binding, as has been shown for other peptides (21, 23-25). 
The observations in the rabbit kidney are in agreement with 
those in membranes from rat brain (12) and pig spieen (9), in 
which regulation of neuropeptide Y binding by guanine nucle-
otides has been demonstrated . 
Our observations indicate further that the soluble receptors 
are functionally coupled to G-proteins, either by reassociation 
of individually solubilized components or, alternatively, by 
acting as a whole and stable complex. The observation that 
for solubilized compared with membrane-embedded receptors 
Iigand binding showed markedly enhanced sensitivity to gua-
nine nucleotides has recently been reported also for so-
matostatin receptors (23). 
It is not yet clear which of the various G-proteins so far 
described might serve as the signal transducer of neuropeptide 
Y binding in the kidney. Several sturlies have shown that the 
neuropeptide Y -induced effects are blocked by pretreatment 
with pertussis toxin. Among the G-proteins ribosylated by 
pertussis toxin, it is Gi that mediates ligand-induced inhibi-
tion of adenylate cyclase activity. Indeed, a reduction of cAMP 
accumulation by neuropeptide Y has been observed in rnany 
tissues including brain (26, 27), cerebral blood vessel (28), 
spieen (9). and a number of celllines endowed with neuropep-
tide Y receptors (29). Thus, a Gi-protein could be associatd 
with the renal neuropeptide Y receptor. However, since recent 
observations in rat sensory neurons provided evidence for a 
Go-induced coupling of neuropeptide Y receptors to calcium 
channels (30), it seems that more than one G-protein might 
function in the signal transduction pathway of this peptide. 
In order to characterize further the neuropeptide Y receptor 
we performed cross-linking studies, thus identifying a 100-
kDa peptide. Half-maximal inhibition of the labeling occurred 
with neuropeptide Y concentrations close to the Kn value, as 
obtained frorn saturation experiments. Therefore, we conclude 
that the 100-kDa polypeptide represents the covalently la-
beled neuropeptide Y receptor. Since reducing conditions did 
not change the labeling pattern, subunit structures caused by 
disulfide bridges appear not to be involved. The molecular 
size of the neuropeptide Y receptor described here compares 
weil with those for some previously purified G-protein-asso-
ciated peptide receptors determined by SDS-PAGE analysis 
(31-33). In contrast to our observations, studies on the cross-
linking of neuropeptide Y to rat brain membranes, using two 
homobifunctional cross-linkers and NHSAB, resulted in spe-
cific labeling of two bands with respective molecular masses 
of 62 and 39 kDa (34). This discrepancy could reflect species-
specific differences as has been described recently for chole-
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FIG. 3. Kinetic experiments and effect of nucleotides on the d.issoci.ation of. 1251-neuropeptide Y 
bound to membranes (pan.el A) and soluble extracts (panel B). Association kinetics (e--e) of 12sJ.. 
neuropeptide Y (0.4 nM) to rabbit kidney membranes (60 #-lg/ml) (pa'nel A) and to CHAPS-solubilized extracts (20 
pg/ml) (panel Bl was exa.mined at 25 "C. After 40 mi~, when equilibrium was reached, the dissociation (0---:0) 
was started by the addition of excess unlabeled neuropeptide Y (final concentration, 1 pM). In parallel studtes, 
GTP'YS (final concentration, 0.1 mM) and unlabeled neuropeptide Y (final concentration, 1 #-IM) were added to 
both fractions, and the t.ime course of dissociation was measured (0--0}. ln control experiments ATPl'S was 
given at a final concentration of 0.1 mM a:fter association to equlibrium, and the specific 1251-neuropeptide Y 
binding was determined (..____.). All data are expressed as percentage of specific 1261-neuropeptide V binding at 
equilibrium and represent averages of two ex.periments performed. in ·triplica.te. 
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F1G. 4. Effect of nucleotides on 1251-neuropeptide Y binding 
to membrane-bound (panel A) and soluble receptors (panel B). 
Rahbit kidney rnembranes (60 pgfml) and CHAPS··solub.ili.zed frac-
tions (20 #-lg/ml> were incubated with 0.4 nM 1251-neuropeptide Y for 
40 min at 25 ·c in the absence or presence of increasing concen· 
trations of the stable nucleotide analogs GTP"YS (0---0) and 
ATP.yS (e--e). Values are the means of .a triplicate determination 
and are expressed as percent of neuropeptide Y binding obtained in 
the absence of the nucleotide triphosphates. 
more recent study concerned with the structural characteriza· 
tion of receptors for neuropeptide Y and peptide YY in various 
tissues including tbe rabbit kidney (37). In these experimentst 
cross-linking peptide YY to kidney membranes resulted in 
the labeling of two major proteins with respective .molecular 
masses of 50 and 38 kDa in addition to another two specific 
but more faint bands in the range of 105 a.nd 130 kDa. The 
employment of other cross-linking reagents as weB as higher 
incubation temperatures with more risk of proteolytic degra-
NPY [Ml 
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FIG. 5. Photoaffinity labeling of neuropeptide Y binding 
sites. Rahbit kidney membranes (100 #-lg/ml) were incubated to 
equilibrium with 0.1 nM 1251-azidobenzoyl neuropeptide Y in the 
presence ( +) or absence {-) of 0.1 #-IM unlabeled neuropeptide Y (lanes 
A) or with 1251-neuropeptide Y and increasing concent~ations of 
unlabeled neuropeptide Y (10_., to 10-u M) (lanes 8) for 4 h at 0 "C. 
After washing and resuspension ofthe membranes in 50 mM HEPES, 
.pH 7.4, containing 5 mM MgCh, cross-linking· was initiated by ·expo· 
sure to UV light (laMs A) or by the addition of NHSAB at a final 
concentration of 1 mMt followed by irradiation (laMs B). All samples 
were aUowed to react for 15 min on ice. The reaction was quenched 
by addition of Tris-HCl, pH 6.8 (final concentration, 170 mM), and 
the products were analyzed by SDS-PAGE under reducing con.ditions 
(100 m.M dithiothreitol) prior to autoradiography. 
dation and the use of 1251-Tyr'l6 peptide YY in contrast to 1251-
Lys4·neuropeptide Y as the affinity Iigand may explain the 
discrepancy between these and our results. It appears rather 
unlikely that the 100-kDa protein described here represents 
an a.rtifactual aggregate of the receptor with another protein 
such as components of G1 or Got since the same protein was 
identified whether the monofunctional neuropeptide Y deriv-
ative or the bifunctional cross-linker NHSAB was used. 
The identification of receptors for neuropeptide Y and 
Solubilization of Active Neuropeptide Y Receptors 18147 
peptide YY in the kidney argues for a role of peptides of the 
pancreatic polypeptide family in the control of kidney func-
tion. In fact, neuropeptide Y has been shown to induce renal 
vasoconstriction and to attenuate renin release from the kid-
ney (38, 39). In addition, sturlies in the isolated perfused rat 
kidney suggested that neuropeptide Y has also some natri-
uretic activity (39). This is of particular interest with respect 
to the distribution of neuropeptide Y binding sites within the 
kidney. According to autoradiographic studies in the rabbit 
kidney, neuropeptide Y bindingisnot confined to the vascu-
lature, but can also be observed over the proximal convoluted 
tubuli (40). It is therefore intriguing to speculate that the 
cortical neuropeptide Y receptors we have characterized here 
play some part in the mediation of the tubular effects of 
neuropeptide Y. 
In summary, in this paper we demoostrate the solubilization 
of neuropeptide Y receptors from rabbit kidney in an active 
form using the detergent CHAPS. Neuropeptide Y binding to 
membrane-embedded and soluble receptors was sensitive to 
guanine nucleotides, suggesting a G-protein-coupled receptor 
type. Cross-linking studies revealed a 100-kDa covalently 
labeled receptor complex. These observations should facilitate 
future studies directed at the purification and molecular char-
acterization of the neuropeptide Y receptor. 
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